Point-of-care (POC) nucleic acid detection technologies are poised to aid gold-standard technologies in controlling the COVID-19 pandemic, yet shortcomings in the capability to perform critically needed complex detection—such as multiplexed detection for viral variant surveillance—may limit their widespread adoption. Herein, we developed a robust multiplexed clustered regularly interspaced short palindromic repeats (CRISPR)-based detection using LwaCas13a and PsmCas13b to simultaneously diagnose severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and pinpoint the causative SARS-CoV-2 variant of concern (VOC)—including globally dominant VOCs Delta (B.1.617.2) and Omicron (B.1.1.529)—all the while maintaining high levels of accuracy upon the detection of multiple SARS-CoV-2 gene targets. The platform has several attributes suitable for POC use: premixed, freeze-dried reagents for easy use and storage; convenient direct-to-eye or smartphone-based readouts; and a one-pot variant of the multiplexed detection. To reduce reliance on proprietary reagents and enable sustainable use of such a technology in low- and middle-income countries, we locally produced and formulated our own recombinase polymerase amplification reaction and demonstrated its equivalent efficiency to commercial counterparts. Our tool—CRISPR-based detection for simultaneous COVID-19 diagnosis and variant surveillance that can be locally manufactured—may enable sustainable use of CRISPR diagnostics technologies for COVID-19 and other diseases in POC settings.
Get full access to this article
View all access options for this article.
References
1.
BiK, Herrera-DiestraJL, BaiY, et al.The risk of SARS-CoV-2 omicron variant emergence in low and middle-income countries (LMICs). medRxiv, 2022; 2022.01.14.22268821; doi: 10.1101/2022.01.14.22268821
2.
BritoAF, SemenovaE, DudasG, et al.Global disparities in SARS-CoV-2 genomic surveillance. medRxiv, 2021; doi: 10.1101/2021.08.21.21262393
3.
European Centre for Disease Prevention and Control and Europe WHORO for. Methods for the Detection and Characterisation of SARS-CoV-2 Variants—First Update What Is New in This Update: Key Messages. World Health Organization. Regional Office for Europe: Copenhagen, Denmark; 2021.
4.
BurkiTK. Lifting of COVID-19 restrictions in the UK and the delta variant. Lancet Respir Med, 2021; 9(8):e85; doi: 10.1016/S2213-2600(21)00328-3
5.
LiuY, RocklövJ. The reproductive number of the delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. J Travel Med, 2021; 28(7); doi: 10.1093/jtm/taab124
GootenbergJS, AbudayyehOO, KellnerMJ, et al.Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a and Csm6. Science (1979), 2018; 360(6387):439–444; doi: 10.1126/science.aaq0179
9.
GootenbergJS, AbudayyehOO, LeeJW, et al.Nucleic acid detection with CRISPR-Cas13a/C2c2. Science (1979), 2017; 356(6336):438–442; doi: 10.1126/science.aam9321
10.
HarringtonLB, BursteinD, ChenJS, et al.Programmed DNA destruction by miniature CRISPR-Cas14 enzymes. Science (1979), 2018; 362(6416):839–842; doi: 10.1126/science.aav4294
11.
BroughtonJP, DengX, YuG, et al.CRISPR–Cas12-based detection of SARS-CoV-2. Nat Biotechnol, 2020; 38(7):870–874; doi: 10.1038/s41587-020-0513-4
12.
FozouniP, SonS, Díaz de León DerbyM, et al.Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. Cell, 2021; 184(2):323.e9–333.e9; doi: 10.1016/j.cell.2020.12.001
13.
JoungJ, LadhaA, SaitoM, et al.Detection of SARS-CoV-2 with SHERLOCK one-pot testing. N Engl J Med, 2020; 383(15):1492–1494; doi: 10.1056/NEJMc2026172
14.
PatchsungM, JantarugK, PattamaA, et al.Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA. Nat Biomed Eng, 2020; 4(12):1140–1149; doi: 10.1038/s41551-020-00603-x
15.
de PuigH, LeeRA, NajjarD, et al.Minimally instrumented SHERLOCK (MiSHERLOCK) for CRISPR-based point-of-care diagnosis of SARS-CoV-2 and emerging variants. Sci Adv, 2021; 7(32); doi: 10.1126/sciadv.abh2944
16.
HeC, LinC, MoG, et al.Rapid and accurate detection of SARS-CoV-2 mutations using a Cas12a-based sensing platform. Biosens Bioelectron, 2022; 198:113857; doi: 10.1016/j.bios.2021.113857
17.
WelchNL, ZhuM, HuaC, et al.Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants. Nat Med, 2022; 28(5):1083–1094; doi: 10.1038/s41591-022-01734-1
18.
Arizti-SanzJ, BradleyA, ZhangYB, et al.Simplified Cas13-based assays for the fast identification of SARS-CoV-2 and its variants. Nat Biomed Eng, 2022; 1–12; doi: 10.1038/s41551-022-00889-z
19.
FaschingCL, ServellitaV, McKayB, et al.COVID-19 variant detection with a high-fidelity CRISPR-Cas12 enzyme. medRxiv, 2021; 2021.11.29.21267041; doi: 10.1101/2021.11.29.21267041
20.
ChaimayoC, KaewnaphanB, TanliengN, et al.Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand. Virol J, 2020; 17(1):177; doi: 10.1186/s12985-020-01452-5
21.
TangY-W, SchmitzJE, PersingDH, et al.Laboratory diagnosis of COVID-19: Current issues and challenges. McAdam AJ. ed. J Clin Microbiol, 2020; 58(6); doi: 10.1128/JCM.00512-20
22.
BaoY, JiangY, XiongE, et al.CUT-LAMP: Contamination-free loop-mediated isothermal amplification based on the CRISPR/Cas9 cleavage. ACS Sens, 2020; 5(4):1082–1091; doi: 10.1021/acssensors.0c00034
23.
Jauset-RubioM, TomasoH, El-ShahawiMS, et al.Duplex lateral flow assay for the simultaneous detection of yersinia pestis and francisella tularensis. Anal Chem, 2018; 90(21):12745–12751; doi: 10.1021/acs.analchem.8b03105
24.
DuttaNK, MazumdarK, GordyJT. The nucleocapsid protein of SARS–CoV-2: A target for vaccine development. Dutch RE. ed. J Virol, 2020; 94(13):e00647-20; doi: 10.1128/JVI.00647-20
25.
AlexandersenS, ChamingsA, BhattaTR. SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication. Nat Commun, 2020; 11(1):6059; doi: 10.1038/s41467-020-19883-7
26.
NimsamerP, MayuramartO, RattanaburiS, et al.Comparative performance of CRISPR-Cas12a assays for SARS-CoV-2 detection tested with RNA extracted from clinical specimens. J Virol Methods, 2021; 290:114092; doi: 10.1016/J.JVIROMET.2021.114092
27.
QianJ, BoswellSA, ChidleyC, et al.An enhanced isothermal amplification assay for viral detection. Nat Commun, 2020; 11(1):5920; doi: 10.1038/s41467-020-19258-y
28.
KonermannS, LotfyP, BrideauNJ, et al.Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell, 2018; 173(3):665.e14–676.e14; doi: 10.1016/j.cell.2018.02.033
29.
YinK, DingX, LiZ, et al.Dynamic aqueous multiphase reaction system for one-pot CRISPR-Cas12a-based ultrasensitive and quantitative molecular diagnosis. Anal Chem, 2020; 92(12):8561–8568; doi: 10.1021/acs.analchem.0c01459
30.
ChenY, MeiY, JiangX. Universal and high-fidelity DNA single nucleotide polymorphism detection based on a CRISPR/Cas12a biochip. Chem Sci, 2021; 12(12):4455–4462; doi: 10.1039/D0SC05717G
31.
MyhrvoldC, FreijeCA, GootenbergJS, et al.Field-deployable viral diagnostics using CRISPR-Cas13. Science (1979), 2018; 360(6387):444–448; doi: 10.1126/science.aas8836
32.
OoiKH, LiuMM, TayJWD, et al.An engineered CRISPR-Cas12a variant and DNA-RNA hybrid guides enable robust and rapid COVID-19 testing. Nat Commun, 2021; 12(1):1739; doi: 10.1038/s41467-021-21996-6
33.
ShinodaH, TaguchiY, NakagawaR, et al.Amplification-free RNA detection with CRISPR–Cas13. Commun Biol, 2021; 4(1):476; doi: 10.1038/s42003-021-02001-8
34.
TengF, GuoL, CuiT, et al.CDetection: CRISPR-Cas12b-based DNA detection with sub-attomolar sensitivity and single-base specificity. Genome Biol, 2019; 20(1):132; doi: 10.1186/s13059-019-1742-z
35.
ZhouT, HuangR, HuangM, et al.CRISPR/Cas13a powered portable electrochemiluminescence chip for ultrasensitive and specific MiRNA detection. Adv Sci, 2020; 7(13):1903661; doi: 10.1002/advs.201903661
36.
LinY, CradickTJ, BrownMT, et al.CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res, 2014; 42(11):7473–7485; doi: 10.1093/nar/gku402
37.
Arizti-SanzJ, FreijeCA, StantonAC, et al.Streamlined inactivation, amplification, and Cas13-based detection of SARS-CoV-2. Nat Commun, 2020; 11(1):5921; doi: 10.1038/s41467-020-19097-x
38.
BallCS, LightYK, KohC-Y, et al.Quenching of unincorporated amplification signal reporters in reverse-transcription loop-mediated isothermal amplification enabling bright, single-step, closed-tube, and multiplexed detection of RNA viruses. Anal Chem, 2016; 88(7):3562–3568; doi: 10.1021/acs.analchem.5b04054
39.
PriyeA, BallCS, MeagherRJ. Colorimetric-luminance readout for quantitative analysis of fluorescence signals with a smartphone CMOS sensor. Anal Chem, 2018; 90(21):12385–12389; doi: 10.1021/acs.analchem.8b03521
40.
PriyeA, BirdSW, LightYK, et al.A smartphone-based diagnostic platform for rapid detection of zika, chikungunya, and dengue viruses. Sci Rep, 2017; 7(1):44778; doi: 10.1038/srep44778
41.
SamacoitsA, NimsamerP, MayuramartO, et al.Machine learning-driven and smartphone-based fluorescence detection for CRISPR diagnostic of SARS-CoV-2. ACS Omega, 2021; 6(4):2727–2733; doi: 10.1021/acsomega.0c04929
42.
PiepenburgO, WilliamsCH, StempleDL, et al.DNA detection using recombination proteins. PLoS Biol, 2006; 4(7):1115–1121; doi: 10.1371/journal.pbio.0040204
43.
SubsoontornP, LohitnavyM, KongkaewC. The diagnostic accuracy of isothermal nucleic acid point-of-care tests for human coronaviruses: A systematic review and meta-analysis. Sci Rep, 2020; 10(1):22349; doi: 10.1038/s41598-020-79237-7
44.
ChaibunT, PuenpaJ, NgamdeeT, et al.Rapid electrochemical detection of coronavirus SARS-CoV-2. Nat Commun, 2021; 12(1):802; doi: 10.1038/s41467-021-21121-7
45.
MayuramartO, NimsamerP, RattanaburiS, et al.Detection of severe acute respiratory syndrome coronavirus 2 and influenza viruses based on CRISPR-Cas12a. Exp Biol Med, 2021; 246(4):400–405; doi: 10.1177/1535370220963793
NguyenLT, SmithBM, JainPK. Enhancement of trans-cleavage activity of Cas12a with engineered CrRNA enables amplified nucleic acid detection. Nat Commun, 2020; 11(1):4906; doi: 10.1038/s41467-020-18615-1
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
